Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Audio Summaries

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia

Aug 7, 2026

The authors aim to address the complexities of managing relapsed or refractory chronic lymphocytic leukemia (RR CLL/SLL) in the context of evolving therapeutic options, particularly in light of targeted agents like covalent Bruton tyrosine kinase inhibitors and venetoclax-based regimens. They emphasize the importance of personalized treatment strategies that consider various factors such as prior therapies, disease biology, and patient preferences, while also highlighting the potential of emerging therapies to improve outcomes.

Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2

Aug 6, 2026

The authors aimed to determine the long-term effects of dexrazoxane on left ventricular (LV) systolic function in childhood cancer survivors treated with doxorubicin, particularly in larger populations. Their findings indicate that dexrazoxane is associated with preserved LV function and a reduced incidence of cardiomyopathy, suggesting it may also lessen the need for intensive cardiomyopathy screening in high-risk patients.

Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4

Aug 6, 2026

The authors present the ASCO Living Guideline for systemic therapy in patients with metastatic castration-resistant prostate cancer, aiming to provide up-to-date recommendations based on rapidly evolving evidence in the field. This guideline is regularly updated by an expert panel to reflect the latest health literature, ensuring that clinicians have access to current best practices while emphasizing the importance of individualized patient care.

Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study

Aug 3, 2026

The authors aimed to evaluate the impact of tumor genomic profiles on the efficacy of adjuvant chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC) participating in the PRODIGE-24/CCTG PA6 study. They found that while modified FOLFIRINOX (mFFX) significantly improved disease-free survival in KRAS-mutated tumors compared to gemcitabine, no benefit was observed in KRAS wild-type tumors, suggesting that current treatment strategies should remain unchanged, although the findings regarding KRAS wild-type tumors warrant further exploration.

Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial

Aug 3, 2026

The authors aimed to evaluate the efficacy and safety of darolutamide, both as a monotherapy and in combination with goserelin, in patients with androgen receptor-positive unresectable locally advanced or recurrent/metastatic salivary gland carcinoma. The results indicated that while darolutamide alone showed limited antitumor activity, the combination with goserelin significantly improved objective response rates and progression-free survival, suggesting a potential chemotherapy-sparing treatment option for this aggressive malignancy.

Dexamethasone-Free Antiemetic Prophylaxis for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: A Multicenter, Phase III, Noninferiority Trial (CIVIC POD)

Jul 31, 2026

The study aimed to determine whether olanzapine could serve as a noninferior alternative to the standard dexamethasone-based regimen for preventing chemotherapy-induced nausea and vomiting (CINV) in children and adolescents receiving highly emetogenic chemotherapy. The results indicated that olanzapine provided comparable control of vomiting without the use of dexamethasone, suggesting it may be a viable corticosteroid-sparing option for pediatric CINV prophylaxis. However, olanzapine was associated with a higher incidence of somnolence.

High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation

Jul 31, 2026

This review addresses the ongoing debate regarding the management of high-risk smoldering multiple myeloma (SMM), particularly the efficacy of early treatment versus observation. The authors highlight recent advancements in risk stratification and the approval of daratumumab for high-risk SMM, which challenges traditional watch-and-wait strategies. They emphasize the need for a patient-centered approach, recognizing that while early intervention may benefit some patients, careful selection is crucial to avoid overtreatment.

Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study

Jul 31, 2026

The Euro-EWING99 study aimed to analyze the characteristics and outcomes of patients with Ewing sarcoma (EWS) to identify prognostic factors influencing survival. With a cohort of 3,395 patients, the study found that overall survival and progression-free survival rates were significantly associated with metastatic status, patient age, tumor volume, and histologic response after neoadjuvant therapy. This research represents the largest series of EWS patients to date and underscores the importance of complete histologic response as a major prognostic indicator.

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Jul 29, 2026

The authors aimed to determine the efficacy of combining mFOLFOX6/bevacizumab with atezolizumab compared to atezolizumab alone as a first-line treatment for patients with deficient DNA mismatch repair metastatic colorectal cancer (dMMR/MSI-H mCRC). The study found that the combination therapy significantly improved progression-free survival and response rates compared to atezolizumab monotherapy, suggesting a potential new standard of care for this patient population.

Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial

Jul 29, 2026

The authors of the FIND trial aimed to determine whether a dynamic surveillance strategy guided by circulating tumor DNA (ctDNA) methylation could enhance the rate of curative-intent therapy for recurrence in patients with nonmetastatic colorectal cancer following curative resection. The results indicated that the ctDNA-guided approach significantly increased the rate of curative treatment and led to earlier detection of resectable metastases compared to standard monitoring, although recurrence rates were similar between the two groups. These findings suggest that ctDNA-guided surveillance may improve outcomes, pending further validation of long-term survival benefits.